Kidney transplantation
Conditions
Interventions
Patients in the standard tacrolimus dose group will receive a dose of 0.20 mg tacrolimus/kg bodyweight per day in two equally divided doses. Patients in the CYP3A5 dosing group will receive a tacrolim
Sponsors
Erasmus Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: Adult recipients (18 years or older) who are to receive an ABO-compatible single-organ kidney transplant from a living donor (related or unrelated) will be eligible for entry into the study.
Exclusion criteria
Exclusion criteria: Patients receiving immunosuppressive therapy (except steroid treatment) within the preceding 28 days except for pretransplant immunosuppressive medication (up to 48 hr before transplantation) will not be included. In addition, patients using medication known to have a pharmacokinetic interaction with tacrolimus will not be asked to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is the proportion of patients reaching target levels (10-15 ng/ml) on day 3 and day 7 after transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the incidence of biopsy-proven acute rejection (BPAR) within the first three months after transplantation and renal function at three months after transplantation. | — |
Contacts
Public ContactT. Gelder, van
's Gravendijkwal 230
Outcome results
None listed